Nikos Pekiaridis | Lightrocket | Getty Pictures
Pfizer on Monday stated it could finish growth of its experimental each day weight reduction tablet after a affected person skilled a liver harm that was doubtlessly brought on by the drug in a trial.
The affected person didn’t expertise any liver-related signs or unwanted effects, a Pfizer spokesperson stated in an announcement. They added that the affected person’s liver enzymes “recovered quickly” after they stopped taking the tablet, which is an oral GLP-1 drug referred to as danuglipron. The assertion means that the affected person’s liver enzymes have been elevated, which frequently signifies injury to cells within the organ and is a matter that has been linked to another weight problems medication.
The case occurred in a trial that shortly elevated the dose of the tablet over a brief time frame, the spokesperson stated. Pfizer’s determination to halt growth of the drug got here after “a evaluation of the totality of data, together with all medical information generated to this point for danuglipron and up to date enter from regulators,” in line with a launch.
“Whereas we’re upset to discontinue the event of danuglipron, we stay dedicated to evaluating and advancing promising packages in an effort to carry revolutionary new medicines to sufferers,” Dr. Chris Boshoff, Pfizer’s chief scientific officer, stated within the launch. He added that the corporate remains to be growing different weight reduction medication.
The announcement provides to a string of setbacks within the firm’s bid to win a slice of the booming marketplace for GLP-1s, which mimic sure intestine hormones to tamp down urge for food and regulate blood sugar. Pfizer is amongst a number of drugmakers racing to carry a extra handy weight reduction medication to an area dominated by weekly injections, however it’s years behind opponents reminiscent of Eli Lilly and Novo Nordisk.
Some Wall Road analysts anticipate the GLP-1 business to be value greater than $150 billion by the early 2030s. Oral GLP-1s might develop to be value $50 billion of that complete, whereas injections would account for the remaining, in line with some analyst estimates.
This isn’t Pfizer’s first set again with danuglipron, particularly, both. The corporate discontinued a twice-daily model of the tablet in December 2023 after sufferers had hassle tolerating the drug in a mid-stage research.
However Pfizer gave the impression to be assured within the once-daily type of danuglipron again in July, when it stated it could begin conducting research within the second half of the yr to judge a number of doses of the tablet.
Regardless of its determination to scrap the drug, Pfizer on Monday stated these research met key targets and confirmed a sure kind and dose of the tablet with the potential to ship “aggressive efficacy and tolerability” in late-stage trials.
The corporate additionally famous that the speed of elevated liver enzymes in individuals who have taken danuglipron is in keeping with authorised GLP-1 medication, which is predicated on a security database of greater than 1,400 sufferers who’ve taken Pfizer’s tablet.
Pfizer scrapped a unique once-daily weight problems tablet again in June 2023 after sufferers who took that drug had larger liver enzyme ranges in a mid-stage trial. Traders have been pessimistic in regards to the firm’s potential within the GLP-1 house ever since.
Nonetheless, Pfizer has different experimental weight problems medication in its pipeline within the early phases of growth that seem to work in a different way from its now-discontinued therapies. That features an oral drug that blocks one other intestine hormone referred to as GIPR, which entered section two trials final yr, and a further once-daily oral GLP-1 in section one trials.
Pfizer believes a drug focusing on GIPR may very well be simpler and simpler for sufferers to tolerate, former Chief Scientific Officer Mikael Dolsten, who has since left the corporate, advised buyers in October. He added that “there are such a lot of purposes for GLP-1s.”
Pfizer’s danuglipron promotes weight reduction by focusing on GLP-1, which can be how Novo Nordisk’s weight reduction injection Wegovy and diabetes remedy Ozempic work. Eli Lilly’s weight reduction injection Zepbound and diabetes shot Mounjaro goal GLP-1 but in addition activate one other intestine hormone referred to as GIP.
The one oral GLP-1 authorised by the Meals and Drug Administration up to now is Novo Nordisk’s Rybelsus, which treats Kind 2 diabetes and raked in about $3.38 billion in gross sales in 2024.
Pfizer’s announcement Monday comes as the corporate regains its footing and recovers its share value after the speedy decline of its Covid enterprise. Pfizer is betting on its pipeline of most cancers medication to ship long-term progress, however has emphasised that weight problems is a key focus.
